Weil Company, Inc. Otonomy, Inc. Transaction History

Weil Company, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2019 Feb 13, 2020	SELL	$2.13 - $3.83 $1,243 - $2,236	-584 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$2.12 - $2.86 $1,238 - $1,670	584 New	584 $1,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Weil Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Weil Company, Inc. with notifications on news.